ARTICLE | Company News
Centaur other research news
July 15, 1996 7:00 AM UTC
Centaur received two $100,000 Phase I SBIRs from the National Eye Institute. One SBIR is to develop drugs to treat the retinal neovascularization that underlies macular degeneration and diabetic retinopathy. The second SBIR is to develop treatments for uveitis and other ocular inflammations. ...